Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
Glavni avtor: | Akter, Anika |
---|---|
Drugi avtorji: | Alam, Marzia |
Format: | Thesis |
Jezik: | English |
Izdano: |
Brac University
2022
|
Teme: | |
Online dostop: | http://hdl.handle.net/10361/17039 |
Podobne knjige/članki
-
Biologics and Biosimilars as Treatment Options for Psoriasis
od: Moya, Amena Khatun
Izdano: (2023) -
Importance of biologics in rheumatoid arthritis management
od: Riyadh, S. M.
Izdano: (2022) -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
od: Afroza, Halima
Izdano: (2024) -
Importance of biologically active agents over other therapies in Rheumatoid Arthritis- a review
od: Mehreen, Elnaj
Izdano: (2021) -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
od: Islam, Nahidul
Izdano: (2023)